Stem Cell Transplantation: Solid Tumors - (0534) — MM 0534 | CIGNA Coverage Update

Cigna modified MM 0534 — its stem cell transplantation coverage policy for solid tumors — effective January 16, 2026. Here's what billing teams need to do.

Cigna Healthcare updated Coverage Policy MM 0534 governing hematopoietic stem cell transplantation (HSCT) for adult and pediatric solid tumor cancers. The change affects 16 CPT codes (38205–38242) and three HCPCS codes (S2140, S2142, S2150) covering the full spectrum of HSCT services — from cell harvesting and transplant preparation to the transplantation itself and allogeneic lymphocyte infusions. If your practice or facility bills HSCT for solid tumor indications, this policy revision changes what you need to document and how you support medical necessity on claims.

Quick-Reference Table

Cigna Stem Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2026

MM 0534 in the Cigna system is the coverage policy for hematopoietic stem cell transplantation applied to solid tumor cancers — not hematologic malignancies, which live in a separate policy. That distinction matters at the claim level. If your team bills CPT 38241 (autologous HPC transplantation) or CPT 38240 (allogeneic HPC transplantation per donor) for a hematologic cancer, this isn't the policy governing that claim.

For solid tumors — think breast cancer, testicular cancer, neuroblastoma, Ewing sarcoma, and similar diagnoses — MM 0534 sets the medical necessity criteria Cigna reviewers apply when evaluating prior authorization requests and claims. Coverage is conditional. All 16 CPT codes and all three HCPCS codes under this policy are considered medically necessary only when the patient meets the applicable selection criteria spelled out in the policy.

Cigna's coverage position doesn't give a blanket approval for HSCT in solid tumors. You need to document the specific indication, the transplant type (autologous vs. allogeneic), and whether the clinical scenario aligns with Cigna's criteria. Submitting CPT 38232 (autologous bone marrow harvesting) or CPT 38206 (blood-derived autologous progenitor cell harvesting) without tight diagnosis coding and supporting documentation is a straight path to claim denial.

Prior authorization is standard practice for HSCT services under major payers, and Cigna is no exception. Before scheduling any transplant-related services for a Cigna-covered patient with a solid tumor diagnosis, confirm prior auth requirements and get approval on record. Failure to do so will cost you the reimbursement regardless of whether the procedure meets medical necessity.

Cigna HSCT for Solid Tumors — Exclusions and Non-Covered Indications

The policy is structured around conditional medical necessity — coverage applies when selection criteria are met. When they aren't met, the services are not covered. For HSCT in solid tumors, Cigna treats indications lacking sufficient clinical evidence as experimental or investigational.

The real exposure here is in allogeneic transplantation for solid tumors. Allogeneic HSCT (CPT 38240, CPT 38230, HCPCS S2142) carries significantly more risk and cost than autologous approaches. Cigna scrutinizes allogeneic requests for solid tumor indications closely. If the diagnosis and clinical scenario don't align with established, evidence-backed criteria in MM 0534, expect a denial — and expect it to stick through appeal unless you have strong clinical documentation.

Cord blood transplantation (HCPCS S2140 for harvesting, S2142 for the transplant itself) follows the same logic. Coverage exists, but only when the clinical criteria are satisfied. Billing S2140 or S2142 without a matching medically necessary indication documented in the record is an audit risk.

Coverage Indications at a Glance

Cigna Stem Cell Transplantation Billing Guidelines and Action Items 2026

CPT, HCPCS, and ICD-10 Codes for Stem Cell Transplantation Under MM 0534

Covered CPT Codes (When Selection Criteria Are Met)

Covered HCPCS Codes (When Selection Criteria Are Met)

Note: No ICD-10-CM codes were specified in the MM 0534 policy data. Work with your transplant physicians to confirm diagnosis code pairings against the selection criteria in the full policy text.

A Note on What This Policy Doesn't Tell You

The policy data for MM 0534 confirms that all 19 codes are medically necessary when criteria are met. It does not publish those criteria in summary form accessible to billing teams — the full selection criteria live in the policy document itself, organized by tumor type and transplant modality. That's where the real work is.

Pull the full policy from Cigna's coverage policy library. Map your most common solid tumor indications against the listed criteria. Build a reference sheet for your auth team that pairs each diagnosis category with the applicable transplant type and the specific criteria language Cigna reviewers use. That documentation discipline is the difference between clean claims and a denial cycle that takes months to resolve.

HSCT for solid tumors is already one of the most scrutinized billing areas in oncology. A policy modification in January 2026 is a signal that Cigna has updated where it draws the covered/not-covered line. Treat this as a reason to review your entire Cigna HSCT workflow — prior auth, charge capture, diagnosis pairing, and documentation standards.